Biota Holdings Limited (BTA)

Biota is an anti-infective drug development company, based in Melbourne, Australia.  Since its initial public offering in 1985, Biota has evolved from a one program research company to a diversified drug discovery and development company with a portfolio of clinical and pre-clinical programs.

Biota receives royalties from two marketed products: Relenza™ (zanamivir) which is partnered globally with GSK; and Inavir® (laninamivir), a second generation influenza drug co-owned with Daiichi Sankyo and marketed by Daiichi Sankyo in Japan.

Key products in development comprise: laninamivir, which is being developed under a contract with BARDA in the US, which is intended to result in a new drug application to the FDA in 2016; vapendavir, which has completed Phase IIb studies designed to establish the effect of the drug on cold symptoms in asthmatics; and RSV, a preclinical, small molecule antiviral intended to provide prophylaxis and treatment of respiratory syncytial virus (RSV) infection.

Melbourne, Australia
Market Cap:
$107 million
No. Shares:














DISCLAIMER: Orient Capital Pty Ltd has taken all reasonable care in publishing the information contained in this Open Briefing®; furthermore, the entirety of this Open Briefing® has been approved for release to the market by the participating company. It is information given in a summary form and does not purport to be complete. The information contained is not intended to be used as the basis for making any investment decision and you are solely responsible for any use you choose to make of the information. We strongly advise that you seek independent professional advice before making any investment decisions. Orient Capital Pty Ltd is not responsible for any consequences of the use you make of the information, including any loss or damage you or a third party might suffer as a result of that use.